Immune cells called B cells make antibodies that fight off invading bacteria, viruses and other foreign substances. During their preparation for this battle, B cells transiently revert to a more ...

Innate lymphoid cells, which curiously behave like T cells even though they don’t recognize specific antigens, show promise as a potential cancer therapeutic. In the years that followed, other groups ...

Lymphoid-derived conventional dendritic cells (L-cDCs) may play a unique function associated with immune suppression and allergy induction, as reported by researchers from Japan. Long thought to arise ...

The immune system is designed to protect us against viruses and bacteria. In autoimmune diseases, however, the immune system instead attacks the body's own cells. Conditions such as systemic lupus ...

By enrolling the world's first participant, the Sarah Cannon Transplant & Cellular Therapy Program at St. David's South Austin Medical Center made this therapy available to patients before it was ...

This case report describes a woman in her 60s diagnosed with primary vitreoretinal lymphoma (PVRL) with leptomeningeal ...

TLS are often linked to enhanced immunotherapy response and increased overall survival in most solid tumors. However, cues that drive differences in TLS formation and function are not clearly ...

The new data bolster Allogene’s efforts to develop a new, easily administered cell therapy that could delay or prevent cancer recurrence.

MB-105, a CD5-targeted CAR-T cell therapy, is being evaluated in a phase 2 trial for relapsed or refractory CD5-positive T-cell lymphoma. The trial, led by Dr. Swaminathan P. Iyer, will assess ...

Pivotal findings for the off-the-shelf cell therapy surpassed William Blair’s expectations and sent Allogene Therapeutics’ stock up more than 50% in pre-market trading Monday morning.